TG Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

TG Therapeutics

24/02/2023 19:32

* TG Therapeutics Inc  TGTX.OQ   TGTX.O  is expected to show
a
fall in quarterly revenue when it reports  results on February
28. 
    * The New York City-based  company is expected to report  a
21.3% decrease in revenue to $1.828 million from $2.32 million a
year ago, according to the mean estimate from 7 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for TG Therapeutics Inc
is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $24​, above​ its last closing price of $16.45. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.33       -0.34      -0.26     Beat    23.9
 Jun. 30 2022  -0.57       -0.51      -0.30     Beat    41.2
 Mar. 31 2022  -0.56       -0.59      -0.51     Beat    14.2​
 Dec. 31 2021  -0.68       -0.63      -0.70     Missed  -10.6
 ​​Sep.        -0.58       -0.56      -0.65     Missed  -15.5
 30 2021                                                
 Jun. 30 2021  -0.50       -0.50      -0.59     Missed  -17.6​
 Mar. 31 2021  -0.52       -0.49      -0.69     Missed  -40.8
 Dec. 31 2020  -0.59       -0.58      -0.71     Missed  -22.1
 This summary was machine generated February 24 at 19:31 GMT. 
All figures in US dollars  unless otherwise stated